ArticleACS applied bio materials2025
Structural Instability of Human Serum Albumin during Microparticles Synthesis.
Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human serum albumin, the most abundant plasma protein, plays vital roles in maintaining oncotic pressure, modulates drugs pharmacokinetics and pharmacodynamics, and features antioxidant and enzyme-like properties. This protein also exhibits high-affinity binding to a wide range of endogenous and exogenous molecules. Combined with its excellent solubility, biocompatibility, biodegradability, low toxicity, and nonimmunogenicity, these properties make human serum albumin an attractive platform for biomedical applications, particularly in drug delivery. This study reports a detailed physicochemical characterization of human serum albumin microparticles obtained via the coprecipitation-cross-linking-dissolution method. The resulting submicron particles are peanut-shaped, exhibit uniform morphology, and show robust mechanical properties, including high stiffness and colloidal stability. However, we observed that the microparticle agglomeration process induces significant structural changes in the protein. Notably, Raman and FTIR spectroscopies highlighted a partial switch from α-helices to β-sheets secondary structure, which leads to diminished HSA binding capability as here demonstrated in the case of hemin. This trade-off between mechanical integrity and biological activity poses challenges for applications requiring native protein interactions, such as the HSA-dependent efficient drug binding and controlled release. Conversely, the reduced binding capability of HSA molecules localized on the surface of MPs implies that these HSA-MPs cannot bind to plasma ligands (e.g., drugs, heme, bacteria toxins). This prevents unwanted ligands from being transported to cellular targets, ensuring that only those located within the HSA-MP are transported. Our findings open new avenues for engineering microsystems that could couple the structural resilience of these microparticles with restored functional surfaces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.